-
Media ReleaseNovartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
-
Media ReleaseReal-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
-
Media ReleaseNovartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
-
Media ReleaseNovartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
-
Media ReleaseFDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
-
Media ReleaseNovartis to fund five innovative ideas to support patients and the sickle cell community
-
Media ReleaseNew Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
-
Media ReleaseNovartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
-
Media ReleaseNovartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
-
Media ReleaseTwo-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
-
Media ReleaseNovartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitis
-
Media ReleaseNovartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study